Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)

European Journal of Heart Failure

Volumn 17, Issue 7, 2015, Pages 707-716

  Cannon, Jane A ^a   Collier, Timothy J ^b   Shen, Li ^a   Swedberg, Karl ^c   Krum, Henry ^d   Van Veldhuisen, Dirk J ^e   Vincent, John ^f   Pocock, Stuart J ^b   Pitt, Bertram ^g   Zannad, Faiez ^h,i   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f PFIZER INC   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h UNIVERSITÉ DE LORRAINE   (France)

ⁱ INSERM   (France)

Author keywords

Clinical trial; Eplerenone; Systolic heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; PLACEBO; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; HEART DEATH; HEART EJECTION FRACTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RIGHT BUNDLE BRANCH BLOCK; HOSPITALIZATION; HUMAN; INTRAVENTRICULAR CONDUCTION DEFECT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; QRS INTERVAL; QRS MORPHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK REDUCTION; SYSTOLIC HEART FAILURE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAPHY; HEART FAILURE; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RANDOM ALLOCATION; SPIRONOLACTONE; STROKE VOLUME; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84947793521     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.303     Document Type: Article

References (23)

1. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM,; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150.
2. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L,; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549.
3. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W,; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329-1338.
4. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL,; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363: 2385-2395.
5. Iuliano S, Fisher S, Karasik P, Fletcher R, Singh S,. QRS duration and mortality in patients with congestive heart failure. Am Heart J 2002; 143: 1085-1091.
6. Zusterzeel R, Curtis JP, Caňos DA, Saunders WE, Selzman KA, Pina IL, Spatz ES, Bao H, Ponirakis A, Varosy PD, Masoudi FA, Strauss DG,. Sex specific mortality risk by QRS morphology and duration in patients receiving CRT: results from the NCDR. J Am Coll Cardiol 2014; 64: 887-894.
7. Brenyo A, Rao M, Barsheshet A, Cannom D, Quesada A, McNitt S, Huang DT, Moss AJ, Zareba W,. QRS axis and the benefit of cardiac resynchronization therapy in patients with mildy symptomatic heart failure enrolled in MADIT-CRT. J Cardiovasc Electrophysiol 2013; 24: 442-448.
8. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang AS,. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013; 34: 3547-3556.
9. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL,. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: 1810-1852.
10. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
11. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, Dickstein K, Ford I, Gorcsan J 3rd, Gras D, Krum H, Sogaard P, Holzmeister J,; EchoCRT Study Group. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013; 369: 1395-1405.
12. Auricchio A, Lumens J, Prinzen FW,. Does cardiac resynchronization therapy benefit patients with right bundle branch block: cardiac resynchronization therapy has a role in patients with right bundle branch block. Circ Arrhythm Electrophysiol 2014; 7: 532-542.
13. Sipahi I, Chou JC, Hyden M, Rowland DY, Simon DI, Fang JC,. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J 2012; 163: 260-267.e3.
14. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, Cannom D, Daubert JP, Eldar M, Gold MR, Goldberger JJ, Goldenberg I, Lichstein E, Pitschner H, Rashtian M, Solomon S, Viskin S, Wang P, Moss AJ,; MADIT-CRT Investigators. Effectiveness of Cardiac esynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011; 123: 1061-1072.
15. Goldenberg I, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Kautzner J, Klempfner R, Kuniss M, Merkely B, Pfeffer MA, Quesada A, Viskin S, McNitt S, Polonsky B, Ghanem A, Solomon SD, Wilber D, Zareba W, Moss AJ,. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med 2014; 370: 1694-1701.
16. Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B,. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010; 12: 617-622.
17. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B,; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
18. Collier TJ, Pocock SJ, McMurray JJ, Zannad F, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B,. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur Heart J 2013; 34: 2823-2829.
19. Lund LH, Jurga J, Edner M, Benson L, Dahlström U, Linde C, Alehagen U,. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J 2013; 34: 529-539.
20. Abdel-Qadir HM, Tu JV, Austin PC, Wang JT, Lee DS,. Bundle branch block patterns and long-term outcomes in heart failure. Int J Cardiol 2011; 146: 213-218.
21. Baldasseroni S, Gentile A, Gorini M, Marchionni N, Marini M, Masotti G, Porcu M, Maggioni AP,; Italian Network on Congestive Heart Failure Investigators. Intraventricular conduction defects in patients with congestive heart failure: left but not right bundle branch block is an independent predictor of prognosis. A report from the Italian Network on Congestive Heart Failure (IN-CHF database). Ital Heart J 2003; 4: 607-613.
22. Reil JC, Robertson M, Ford I, Borer J, Komajda M, Swedberg K, Tavazzi L, Böhm M,. Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. Eur J Heart Fail 2013; 15: 1044-1052.
23. Hawkins NM, Wang D, McMurray JJ, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Pocock SJ, Ostergren J, Michelson EL, Dunn FG,; CHARM Investigators and Committees. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. Eur J Heart Fail 2007; 9: 510-517.